Literature DB >> 1868680

Measuring compliance in methadone maintenance patients: use of a pharmacologic indicator to "estimate" methadone plasma levels.

K Wolff1, A Hay, D Raistrick, R Calvert, M Feely.   

Abstract

A quantitative indicator of compliance is not available for methadone--the drug of choice for the treatment of opioid addiction. We successfully used low-dose phenobarbital (a valid pharmacologic indicator) to measure compliance by incorporating the drug into the methadone medication of patients attending an addiction unit. Plasma phenobarbital and methadone concentrations were measured in 20 (11 clinic-based and 9 community-based) patients receiving long-term treatment with the phenobarbital level-to-dose ratio, together with interviews, to validate methadone measurements and to monitor compliance. Patients attending the unit on a daily basis and who consumed their medication in the clinic were substantially more compliant than community-based patients. Laboratory measurements of phenobarbital and methadone helped to identify the use of illicit methadone, as well as incorrect self-administration, such as the consumption of several days' dosage at one time.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1868680     DOI: 10.1038/clpt.1991.125

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 2.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Methadone maintenance treatment. Treatment should be tailored for each patient.

Authors:  K Wolf; A Hay; D Raistrick
Journal:  BMJ       Date:  1995-02-18

4.  Steady-state pharmacokinetics of methadone in opioid addicts.

Authors:  K Wolff; A W Hay; D Raistrick; R Calvert
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial.

Authors:  J Hill; H Bird; S Johnson
Journal:  Ann Rheum Dis       Date:  2001-09       Impact factor: 19.103

6.  Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.

Authors:  Mohammad-Reza Shiran; Martin S Lennard; Mohammad-Zafar Iqbal; Oldwale Lagundoye; Nicholas Seivewright; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

7.  Initial evaluation of low-dose phenobarbital as an indicator of compliance with antimalarial drug treatment.

Authors:  J Karbwang; W Fungladda; C E Pickard; S Shires; A Hay; M Feely
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.